Fluorescent Cynomolgus CD20 Full Length Protein (VLP)

ユーザーレビュー
製品番号/仕様
価格
数量
CD0-C52P4-20ug
$620.00
CD0-C52P4-100ug
$1235.00
CD0-C52P4-500ug (250ug X 2)
$4305.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Application

    1. Immunization
    2. Cell based assay (FACS or functional assay)
    3. Screening (ELISA)
  • Synonyms

    MS4A1, CD20, MS4A-1

  • Source

    Fluorescent Cynomolgus CD20 Full Length Protein (VLP) (CD0-C52P4) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # M4ZHZ6-1).

    Predicted N-terminus: Met 1

  • Molecular Characterization

    This protein carries a GFP tag.

    *The isotype control of empty/mock VLP (Cat. No. VLP-NF2P4) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

    2. Synthesis Process

      Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

  • Conjugate

    GFP

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 530 nm

  • Formulation

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

    Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • Bioactivity-ELISA

     CD20 ELISA

    Immobilized Fluorescent Cynomolgus CD20 Full Length Protein (VLP) (Cat. No. CD0-C52P4) at 10 μg/mL (100 μL/well) can bind Rituximab biosimilar (Cat. No. CD0-M36) with a linear range of 0.01-0.313 μg/mL (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Fluorescent Cynomolgus CD20 Full Length Protein (VLP) (Cat. No. CD0-C52P4) at 5 μg/mL (100 μL/well) can bind Obinutuzumab biosimilar with a linear range of 0.3-5 ng/mL (Routinely tested).

    Protocol
  •  CD20 ELISA

    Immobilized Fluorescent Cynomolgus CD20 Full Length Protein (VLP) (Cat. No. CD0-C52P4) at 10 μg/mL (100 μL/well) can bind Ofatumumab biosimilar with a linear range of 0.005-0.078 μg/mL (Routinely tested).

    Protocol
  • Bioactivity-FACS

     CD20 FACS

    2e5 of Anti-CD20 CAR-293 Cells were stained with 100 μL of 10 μg/mL of Fluorescent Cynomolgus CD20 Full Length Protein (VLP) (Cat. No. CD0-C52P4) and isotype control protein respectively. GFP signal was used to evaluate the binding activity (Routinely tested).

    Protocol
  • Identity-DLS

     CD20 DLS

    The mean peak Radius of VLP is 60-80 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

ユーザーレビュー
コメントを投稿

バックグランド

A B-lymphocyte surface antigen expressed from pre-B to mature B cells, but absent on plasma cells. It functions as a calcium channel and is a validated immunotherapy target, famously exploited by rituximab for treating B-cell malignancies and autoimmune disorders.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    B-lymphocyte antigen CD20

  • カテゴリ:

  • 市販の医薬品数:

    35 詳細

  • 治験医薬品数:

    132 詳細

  • 最新の開発ステージ:

    Approved

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8